NO20055180L - Sammensetninger som innbefatter makrolid T-celle immunomodulerende eller -immunosupressive stoffer i kombinasjon med antibakterielle stoffer - Google Patents

Sammensetninger som innbefatter makrolid T-celle immunomodulerende eller -immunosupressive stoffer i kombinasjon med antibakterielle stoffer

Info

Publication number: NO20055180L
Authority: NO; Norway
Prior art keywords: bacterial; macrolide; agents; compositions; combination
Prior art date: 2003-04-04

Application number

NO20055180A

Other languages

English (en)

Norwegian (no)

Other versions

NO20055180D0 (no

Inventor

Johannes Hildebrandt

Maximillan Grassberger

Stefan Hirsch

Anton Stuetz

Nabila Sekkat

Carle Paul

Neil Stewart Ryder

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-04-04

Filing date

2005-11-03

Publication date

2006-01-04

2005-11-03 Application filed by Novartis Ag filed Critical Novartis Ag

2005-11-03 Publication of NO20055180D0 publication Critical patent/NO20055180D0/no

2006-01-04 Publication of NO20055180L publication Critical patent/NO20055180L/no

Links

210000001744 T-lymphocyte Anatomy 0.000 title abstract 2
239000003242 anti bacterial agent Substances 0.000 title abstract 2
230000002519 immonomodulatory effect Effects 0.000 title abstract 2
239000003018 immunosuppressive agent Substances 0.000 title abstract 2
239000003120 macrolide antibiotic agent Substances 0.000 title abstract 2
229940125721 immunosuppressive agent Drugs 0.000 title 1
239000000203 mixture Substances 0.000 title 1
ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 abstract 2
230000003466 anti-cipated effect Effects 0.000 abstract 2
230000001580 bacterial effect Effects 0.000 abstract 2
MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 abstract 2
GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 abstract 1
208000002874 Acne Vulgaris Diseases 0.000 abstract 1
208000034309 Bacterial disease carrier Diseases 0.000 abstract 1
208000035143 Bacterial infection Diseases 0.000 abstract 1
201000004624 Dermatitis Diseases 0.000 abstract 1
206010012438 Dermatitis atopic Diseases 0.000 abstract 1
206010012442 Dermatitis contact Diseases 0.000 abstract 1
CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 abstract 1
229930182566 Gentamicin Natural products 0.000 abstract 1
206010062016 Immunosuppression Diseases 0.000 abstract 1
UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 abstract 1
206010034133 Pathogen resistance Diseases 0.000 abstract 1
208000003251 Pruritus Diseases 0.000 abstract 1
201000004681 Psoriasis Diseases 0.000 abstract 1
206010039793 Seborrhoeic dermatitis Diseases 0.000 abstract 1
206010000496 acne Diseases 0.000 abstract 1
239000013543 active substance Substances 0.000 abstract 1
201000008937 atopic dermatitis Diseases 0.000 abstract 1
208000010668 atopic eczema Diseases 0.000 abstract 1
208000022362 bacterial infectious disease Diseases 0.000 abstract 1
229960003405 ciprofloxacin Drugs 0.000 abstract 1
208000010247 contact dermatitis Diseases 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
229960003276 erythromycin Drugs 0.000 abstract 1
239000002955 immunomodulating agent Substances 0.000 abstract 1
230000002584 immunomodulator Effects 0.000 abstract 1
229940121354 immunomodulator Drugs 0.000 abstract 1
230000001506 immunosuppresive effect Effects 0.000 abstract 1
229960003444 immunosuppressant agent Drugs 0.000 abstract 1
230000001861 immunosuppressant effect Effects 0.000 abstract 1
230000007803 itching Effects 0.000 abstract 1
229960001699 ofloxacin Drugs 0.000 abstract 1
150000004492 retinoid derivatives Chemical class 0.000 abstract 1
201000004700 rosacea Diseases 0.000 abstract 1
208000008742 seborrheic dermatitis Diseases 0.000 abstract 1
231100000075 skin burn Toxicity 0.000 abstract 1
NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 abstract 1
229960001940 sulfasalazine Drugs 0.000 abstract 1
NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 abstract 1
239000011885 synergistic combination Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Dermatology (AREA)
Epidemiology (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

NO20055180A 2003-04-04 2005-11-03 Sammensetninger som innbefatter makrolid T-celle immunomodulerende eller -immunosupressive stoffer i kombinasjon med antibakterielle stoffer NO20055180L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB0307862.3A GB0307862D0 (en)	2003-04-04	2003-04-04	Pharmaceutical composition
PCT/EP2004/003510 WO2004087143A1 (en)	2003-04-04	2004-04-02	Compositions comprising macrolide t-cell immunomodulators or immunosuppressants in combination with antibacterials

Publications (2)

Publication Number	Publication Date
NO20055180D0 NO20055180D0 (no)	2005-11-03
NO20055180L true NO20055180L (no)	2006-01-04

Family

ID=9956225

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20055180A NO20055180L (no)	2003-04-04	2005-11-03	Sammensetninger som innbefatter makrolid T-celle immunomodulerende eller -immunosupressive stoffer i kombinasjon med antibakterielle stoffer

Country Status (13)

Country	Link
US (1)	US20070117764A1 (sr)
EP (1)	EP1613316A1 (sr)
JP (1)	JP2006522056A (sr)
CN (1)	CN1771035A (sr)
AU (1)	AU2004226818A1 (sr)
BR (1)	BRPI0409190A (sr)
CA (1)	CA2521260A1 (sr)
GB (1)	GB0307862D0 (sr)
IS (1)	IS8104A (sr)
MX (1)	MXPA05010700A (sr)
NO (1)	NO20055180L (sr)
RS (1)	RS20050731A (sr)
WO (1)	WO2004087143A1 (sr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0307864D0 (en) *	2003-04-04	2003-05-14	Novartis Ag	Pharmaceutical composition
CN101711869B (zh) *	2009-09-23	2012-04-04	王国礼	喹诺酮类抗菌药物在银屑病治疗中的应用
JP7446594B2 (ja) *	2017-07-21	2024-03-11	学校法人東京薬科大学	好中球細胞外トラップ形成促進剤

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BR0209474A (pt) *	2001-05-09	2006-02-07	Novartis Ag	Métodos para imunomodulação seletiva
US20030021816A1 (en) *	2001-06-06	2003-01-30	Sewon Kang	Compositions and methods for use against acne-induced inflammation and dermal matrix-degrading enzymes
WO2003004098A1 (en) *	2001-07-06	2003-01-16	Sucampo Ag	Composition for topical administration comprising an interleukin-2 inhibitor and an antimicrobial agent
US20030207819A1 (en) *	2002-05-02	2003-11-06	Moskowitz Roland W.	Compositions and methods for treating inflammatory connective tissue diseases

2003
- 2003-04-04 GB GBGB0307862.3A patent/GB0307862D0/en not_active Ceased
2004
- 2004-04-02 US US10/550,359 patent/US20070117764A1/en not_active Abandoned
- 2004-04-02 BR BRPI0409190-6A patent/BRPI0409190A/pt not_active IP Right Cessation
- 2004-04-02 EP EP04725330A patent/EP1613316A1/en not_active Withdrawn
- 2004-04-02 CN CNA2004800092489A patent/CN1771035A/zh active Pending
- 2004-04-02 AU AU2004226818A patent/AU2004226818A1/en not_active Abandoned
- 2004-04-02 MX MXPA05010700A patent/MXPA05010700A/es unknown
- 2004-04-02 CA CA002521260A patent/CA2521260A1/en not_active Abandoned
- 2004-04-02 JP JP2006504963A patent/JP2006522056A/ja active Pending
- 2004-04-02 WO PCT/EP2004/003510 patent/WO2004087143A1/en not_active Ceased
- 2004-04-02 RS YUP-2005/0731A patent/RS20050731A/sr unknown
2005
- 2005-10-31 IS IS8104A patent/IS8104A/is unknown
- 2005-11-03 NO NO20055180A patent/NO20055180L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
US20070117764A1 (en)	2007-05-24
WO2004087143A1 (en)	2004-10-14
JP2006522056A (ja)	2006-09-28
BRPI0409190A (pt)	2006-04-11
GB0307862D0 (en)	2003-05-14
IS8104A (is)	2005-10-31
CA2521260A1 (en)	2004-10-14
NO20055180D0 (no)	2005-11-03
CN1771035A (zh)	2006-05-10
RS20050731A (sr)	2007-11-15
MXPA05010700A (es)	2005-12-12
AU2004226818A1 (en)	2004-10-14
EP1613316A1 (en)	2006-01-11

Legal Events

Date	Code	Title	Description
2008-11-24	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
AU2015205914B2 (en)	2016-07-28	1,6- diazabicyclo [3,2,1] octan- 7- one derivatives and their use in the treatment of bacterial infections
WO2007118130A3 (en)	2008-06-05	Antibacterial agents
WO2006002047A3 (en)	2006-03-23	Antibacterial agents
WO2008041966A3 (en)	2008-12-11	Broad spectrum antibacterial compounds
AU2003291227A1 (en)	2004-06-07	Antibacterial agents
EP1560821B8 (en)	2010-05-19	Antibacterial agents
EP4100058A4 (en)	2024-06-12	IMMUNOGENIC COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF MICROBIAL INFECTIONS
WO2007016610A3 (en)	2007-06-07	Antibacterial agents
WO2006020561A3 (en)	2006-08-24	Antibacterial agents
WO2006081182A3 (en)	2006-09-21	Antibacterial agents
NO20055180L (no)	2006-01-04	Sammensetninger som innbefatter makrolid T-celle immunomodulerende eller -immunosupressive stoffer i kombinasjon med antibakterielle stoffer
WO2006017468A3 (en)	2006-07-13	Antibacterial agents
TN2009000495A1 (en)	2011-03-31	Macrocycles and their uses
Singh et al.	2016	Comparative antimicrobial activity of tea tree oil (Melaleuca oil) and common topical antimicrobials against bacteria associated with wound and topical infections
Wang et al.	2024	Pre-exposure to peracetic acid followed by UV treatment for deactivating vancomycin-resistant Enterococcus faecalis through intracellular attack
WO2011019736A3 (en)	2011-06-23	System and method for controlling bacterial persister cells with weak electric currents
Ozuguz et al.	2014	Evaluation of nasal and oropharyngeal flora in patients with acne vulgaris according to treatment options
Yamagishi et al.	2017	Antimicrobial activity of fidaxomicin against Clostridium difficile clinical isolates in Aichi area in Japan
WO2006001844A3 (en)	2006-10-19	β-CYCLODEXTRIN DERIVATIVES AND THEIR USE AGAINST ANTHRAX LETHAL TOXIN
WO2007133803A3 (en)	2008-01-10	Treatment of mycobacterial infections
ATE509018T1 (de)	2011-05-15	Als antimikrobielle mittel geeignete bisindolpyrrole
WO2019173159A8 (en)	2019-10-10	Ergothioneine compositions and methods for maintaining and/or increasing vitamin c levels in cells and organisms
CR11469A (es)	2010-07-09	Aminotiazoles y sus usos
WO2007092590A3 (en)	2007-11-08	Anti-mycobacterial formulation comprising octanesulphonylacetamide (osa), nonanesulphonylacetamide (nsa) and decanesulphonylacetamide (dsa)
Tan et al.	2011	Increased rifampicin resistance in blood isolates of meticillin-resistant Staphylococcus aureus (MRSA) amongst patients exposed to rifampicin-containing antituberculous treatment